Sexual Wellness

An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder in premenopausal women, also studied for broader sexual dysfunction.

A naturally occurring neuropeptide involved in social bonding, trust, and reproduction, FDA-approved for labor induction.

Synthetic gonadotropin-releasing hormone used diagnostically and therapeutically for reproductive hormone assessment and fertility.

An FDA-approved GnRH agonist used for prostate cancer, endometriosis, and precocious puberty through hormonal suppression.

An FDA-approved GnRH agonist used for prostate cancer, endometriosis, central precocious puberty, and discussed in the peptide community for post-cycle hormonal resets.

Placental glycoprotein hormone that acts as an LH-receptor agonist — used clinically as an ovulation trigger in IVF and off-label in men to stimulate endogenous testosterone and preserve fertility during or after exogenous androgen use.

The native hypothalamic decapeptide that sits at the top of the reproductive axis, releasing LH and FSH in pulses to drive gonadal steroidogenesis.

An FDA-approved GnRH agonist delivered intranasally — the only GnRH agonist in routine US nasal-spray practice — used for endometriosis and central precocious puberty.

An FDA-approved GnRH agonist nonapeptide delivered via a once-yearly subcutaneous hydrogel implant, used for central precocious puberty (Supprelin LA) and historically for advanced prostate cancer (Vantas).

An FDA-approved GnRH receptor antagonist decapeptide used for advanced prostate cancer — suppresses testosterone within days with no initial flare, in contrast to GnRH agonists like leuprolide and triptorelin.

An endogenous gonadal dimeric protein hormone (TGF-β superfamily) that selectively suppresses pituitary FSH secretion and is used clinically as a biomarker for fertility, granulosa cell tumors, and prenatal screening.

An FDA-approved synthetic prostaglandin E1 (PGE1) — a 20-carbon eicosanoid lipid, not a peptide — used as an intracavernosal injection, urethral suppository, or topical cream for erectile dysfunction, and as an intravenous infusion in neonates to maintain ductus arteriosus patency in ductus-dependent congenital heart disease.

A urine-derived gonadotropin preparation containing both FSH and LH activity, used for ovulation induction and controlled ovarian stimulation in IVF — the original injectable fertility drug, still in use as Menopur and HP-hMG formulations.

The active isomer of clomiphene, a selective estrogen receptor modulator (SERM) that raises testosterone while preserving fertility. Not FDA-approved as a standalone drug, but widely available through compounding pharmacies.

A GnRH agonist nonapeptide approved in Europe and Canada since the 1980s for prostate cancer, endometriosis, fibroids, IVF, and precocious puberty — but never FDA-approved in the US.

A naturally occurring neuropeptide that plays a central role in reproductive hormone regulation and fertility.

A synthetic melanocortin peptide studied for tanning, sexual function, and appetite suppression. Not FDA-approved; the FDA has issued public warnings against its use.

A synthetic dipeptide bioregulator (Glu-Asp) from the Khavinson system, studied for bladder function support, urinary health, and age-related urogenital decline.

A synthetic tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, studied for vascular protection, endothelial function, and age-related cardiovascular decline.

A synthetic short peptide bioregulator (commonly cited as the tetrapeptide Lys-Glu-Asp-Pro) from the Khavinson program, positioned as a prostate-tissue-specific regulator and studied in rodent models for benign prostatic hyperplasia, chronic prostatitis, and age-related prostate function decline.

A synthetic tetrapeptide bioregulator (commonly cited as Lys-Glu-Asp-Gly, KEDG) from the Khavinson program, positioned as the testicular tissue-targeted short peptide and discussed for age-related decline in Leydig cell function, male reproductive aging, and androgen deficiency.